MedinCell has been collaborating for more than 10 years with IRD, IRSS and CIRDES to conduct in vivo studies in Burkina Faso about tackling residual transmission of Malaria. These partners provide theoretical and practical scientific expertise on malaria and vectors, and the essential field infrastructure to support the demonstration of a 3-month active injectable ivermectin formulation against malaria vectors. Administered once to exposed populations at the start of the rainy season, which is the period of highest risk of transmission, the investigational product could have a significant impact on malaria incidence and prevalence in Africa where the burden is the highest. Malaria remains pandemic in 91 countries representing 50% of the world's population. According to WHO estimates, 228 million people were infected worldwide in 2018, 93% of them in Africa, leading to 405,000 deaths. Children under 5 years are the most vulnerable, accounting for 67% of deaths from malaria. Ivermectin has a record of use as a safe and effective drug to treat several parasitic diseases, such as river blindness. Its safety in continuous dosing over 1-month has been demonstrated by a recent randomized placebo-controlled clinical trial sponsored by MedinCell, in which ivermectin was orally administered daily, to simulate the continuous release of the active substance by a long-acting injection. This study and the expert review recently conducted by Pr. Jacques Descotes about the safety profile of ivermectin supports the progress of MedinCell programs using Ivermectin. Unitaid aims at expanding access to much-needed drugs and diagnostics. Unitaid has committed to accelerate the impact of long-acting technologies in LMICs by supporting the development of innovative products that could redefine prevention and treatment of infectious diseases like HIV, TB, Malaria and hepatitis C. MedinCell has been the first private company to receive support from Unitaid to help develop and commercialize long-acting medicine. By supporting MedinCell and the consortium, Unitaid is investing in finding additional solutions to prevent the spread of malaria and in making them more accessible. According to the agreement, the Unitaid-funded Medicines Patent Pool - in charge of licensing agreements for the exploitation of patents for medicines in low- and middle-income countries - will receive a non-exclusive royalty free license to ensure distribution of the final product via public sector in LMICs.